公开(公告)号：US20220162217A1

公开(公告)日：2022-05-26

申请号：US17479530

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Xuri Gao ,  Ruichao Shen ,  Yong He ,  Jiajun Zhang ,  Joseph D. Panarese ,  Hui Cao ,  Xuechao Xing ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11319325B1

公开(公告)日：2022-05-03

申请号：US17479669

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jiajun Zhang ,  Xiaowen Peng ,  Joseph D. Panarese ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/20

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200377519A1

公开(公告)日：2020-12-03

申请号：US16891401

申请日：2020-06-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Xiaowen Peng ,  Wei Li ,  Jorden Kass ,  Hui Cao ,  Byung-Chul Suh ,  Jiajun Zhang ,  Yat Sun Or

IPC: C07D498/20 ,  C07D487/20

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.